In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Lisata Therapeutics (LSTA – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $2.70.
According to TipRanks, Pantginis is an analyst with an average return of -5.4% and a 34.47% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Panbela Therapeutics, Onconova Therapeutics, and Celldex.
Lisata Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.
See Insiders’ Hot Stocks on TipRanks >>
LSTA market cap is currently $21.53M and has a P/E ratio of -0.24.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Read More on LSTA:
- Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Lisata Therapeutics announces FDA ODD granted to LSTA1
- Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time
- Lisata Therapeutics malignant glioma treatment granted FDA orphan status
- Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
